Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Taxanes in combined modality therapy for solid tumors.

H Choy1

  • 1Center for Radiation Oncology, B902 TVC, Vanderbilt University Medical Center, 22nd Ave at Pierce, Nashville, TN 37232-5671, USA.

Critical Reviews in Oncology/Hematology
|March 15, 2001
PubMed
Summary

Taxanes, like paclitaxel and docetaxel, show promise in treating solid tumors and are being studied with radiation therapy. Clinical trials explore their effectiveness and tolerability in various cancers, including lung and head and neck cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Improving outcomes in the treatment of locally-advanced NSCLC with gemcitabine.

Lung cancer (Amsterdam, Netherlands)·2005
Same author

A phase I trial of outpatient weekly irinotecan/carboplatin and concurrent radiation for stage III unresectable non small-cell lung cancer: a Vanderbilt-Ingram Cancer Center Affiliate Network Trial.

Clinical lung cancer·2004
Same author

Topoisomerase I inhibitors in the combined modality therapy of lung cancer.

Clinical lung cancer·2004
Same author

A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial.

Clinical lung cancer·2004
Same author

Management of unresectable non-small cell carcinoma of the lung (NSCLC).

Lung cancer (Amsterdam, Netherlands)·2004

Area of Science:

  • Oncology
  • Medical Oncology
  • Cancer Research

Background:

  • Taxanes (paclitaxel, docetaxel) are novel antimitotic agents with demonstrated activity against solid tumors.
  • Taxanes induce G2/M cell cycle arrest, a radiosensitive phase, making them candidates for combination with radiation therapy.
  • Growing information on docetaxel's tolerability and utility is becoming available.

Purpose of the Study:

  • To review prominent clinical trials combining taxanes with radiation therapy for solid tumors.
  • To highlight the use of taxanes in treating non-small cell lung cancer (NSCLC) and head and neck cancers.
  • To discuss the potential utility and tolerability of docetaxel in combination cancer treatment.

Main Methods:

  • Review of clinical trials investigating taxane-based chemotherapy combined with radiation therapy.

Related Experiment Videos

  • Analysis of studies focusing on non-small cell lung cancer (NSCLC), head and neck cancers, and other solid tumors.
  • Inclusion of data on the tolerability and efficacy of docetaxel in concurrent chemoradiation settings.

    • Main Results:

    • Taxanes demonstrate significant activity as single agents and in combination therapies for various solid tumors.
    • Combination of taxanes with radiation therapy is under extensive clinical investigation.
    • Studies show taxanes' effectiveness in non-small cell lung cancer (NSCLC) and head and neck cancers, with emerging data for other tumor types.

    Conclusions:

    • Taxanes are effective antimitotic agents with significant activity in solid tumors.
    • The radiosensitizing properties of taxanes support their use in combination with radiation therapy.
    • Ongoing trials are evaluating the tolerability and utility of taxanes, particularly docetaxel, in multimodal cancer treatment strategies.